Home » Topics » Regulatory » EMA

EMA
RSS

CHMP recommends extended indication for Rebif in patients with early signs of MS

Nov. 21, 2011

Starpharma reaches agreement with EMA on phase III program for VivaGel

Nov. 21, 2011

AstraZeneca receives positive CHMP opinion for vandetanib

Nov. 21, 2011

EMA accepts Nuedexta MAA for filing

Nov. 18, 2011

AMT's gene therapy for hemophilia B given orphan drug status in Europe

Nov. 16, 2011

FDA and EMA accept Astellas' submissions for mirabegron

Nov. 15, 2011

Merck Sharp & Dohme withdraws MAA for fixed-dose combination of sitagliptin and pioglitazone

Nov. 15, 2011

EC withdraws marketing authorization for Ablavar

Nov. 14, 2011

Novartis presents key developments of third quarter 2011

Nov. 11, 2011

Discovery Labs' lucinactant gains European orphan drug status

Nov. 4, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 15, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...